Stay Informed While Earning Oncology CME Credits
The cancer treatment landscape is rapidly changing with new discoveries and expert guidance emerging. As research, testing and treatment strategies continue to evolve, clinicians must keep abreast of the latest data on molecular mechanisms, emerging therapies, current standards of care, expert guideline updates, and new strategies for treatment. Whether you are looking for education on the value and interpretation of real-world evidence for clinical decision making, translation of efficacy and safety of therapeutic agents to decisions for your patients, or resources to share with patients and families navigating their cancer journey, you’ll find educational activities and resources here to help improve your knowledge and help your patients better take part in their care.
Our activities offer many credit types, including CME, AAFP Prescribed Credit, CNE, CPE, ABIM MOC, and ABP MOC. Each activity has been designed to meet the requirements for CME for MIPS. See each activity’s information page for the exact credit type and amount of credit offered.
Racial and Ethnic Disparities and Health Inequities in Oncology Care
|
|
While oncology treatments continue to advance in the era of modern medicine, the healthcare system remains plagued by longstanding health inequities. It is imperative that all members of the health care team recognize their important roles in providing education, services, and equitable care for all patients. In this OnDemand CME Outfitters webcast, expert faculty discuss the impact of unconscious and systemic biases, SDoH, and regional, racial, and ethnic disparities and provide tools and resources to improve oncology care for all patients. |
Action Steps to Address Inequities in Cancer Care Access, Treatment, and Outcomes in Your Community
|
|
In this OnDemand webcast, expert faculty discuss the treatment obstacles many patients from underserved communities face, especially for cancer therapies, such as ICIs. They recommend practices clinicians can implement to help their patients overcome barriers to cancer therapies. Finally, faculty help clinicians develop strategies to make changes on a personal level and within their practice, and suggest ways to break down structural inequities within their community to improve outcomes for their patients. |
Getting Ahead of irAEs: Fostering Change in Structural Systems for Disadvantaged Populations
|
|
In this OnDemand WebCast, expert faculty discuss how to use SDM to communicate treatment options, including ICIs, and build trust with patients to improve outcomes. They present an overview of ICIs, the indications for use and common AEs, and then outline best practices and protocols for patients taking ICIs. Finally, faculty address how to diagnosis and manage AEs to provide better adherence to ICI therapies for all patients with cancer. |
Root Cause Analysis: Examining Structural Racism and SDoH to Combat Inequities in Cancer Care
|
|
In this CME Outfitters OnDemand Webcast, expert faculty discuss how structural inequities rooted within health systems impact members of historically marginalized groups. They describe major health care barriers and outline how institutional analyses can help identify and rectify these disparities. Resources to improve health equity, including partnerships with organizations such as Project ECHO, demonstrate how these programs can be implemented. Finally, opportunities for introspection within the health care systems are presented. |
Unequal Burden: Understanding the Roots of Health Disparities in Cancer Care
|
|
In this OnDemand webcast, expert faculty discuss the inequities that impact members of historically marginalized groups and the factors that contribute to these disparities. They will review the groups impacted, the role social determinants of health play, and strategies to reduce or eliminate disparities for these communities, leading to better access to screenings, diagnosis, treatment, and outcomes. |
Informed Therapy for Black Women with Triple-Negative Breast Cancer: Meeting Them Where They Are and Moving Toward Better Outcomes
|
|
In this CMEO Webcast, expert faculty discuss the health inequities Black women with TNBC face, in screening, treatment, and outcomes, and how these disparities relate to the social determinants of health. In addition, they will present treatment protocols and guidelines, including the latest agents approved to treat TNBC, to help reduce these inequities. Lastly, faculty outline how understanding the obstacles and barriers that Black women face can help inform better treatments and outcomes. |
Advanced Ovarian Cancer: New Insights on Making the Most of Mutations and Biomarkers to Inform Treatment Plans
|
|
In this CME Outfitters OnDemand activity, expert faculty discuss the importance of germline and somatic genetic, genomic, and other biomarker testing, and how this testing informs treatment plans utilizing newly approved and emerging agents based on their efficacy with specific mutations and biomarkers. |
Disentangling Gendered Cancer Care: Improving Cervical and Breast Screenings for Sexual and Gender Minority People
|
|
This CME Outfitters OnDemand Webcast focuses on the disparities and unique health care needs of sexual and gender minority people as it aims to raise HCP awareness of the damaging impact of hetero- or cis-presumptive clinical environments, language, and interactions, and showcases processes that create an inclusive, culturally competent, and trusting environment. |
Ahead of the Game: Updates in Multi-Cancer Early Detection Tests
|
|
This CMEO OnDemand activity features expert faculty discussing the benefits and limitations of current cancer screening approaches as well as emerging MCED tests and the considerations that guide the use of these tests. |
Combos are Complicated! Navigating the Balance of Efficacy and Safety in Advanced Endometrial Cancer
|
|
This CMEO OnDemand activity provides learners with the rationale and data for new combination therapies approved for advanced EC as well as best practices to improve patient adherence to their regimens, with the goal of early recognition and appropriate management of AEs. |
Determining a Patient's Risk: Identifying Rapid Progression of Follicular Lymphoma
|
|
This first installment in a CME Outfitters’ series on follicular lymphoma reviews the risk assessment techniques available to identify patients with FL who may experience POD24. Join Dr. Casulo and Dr. Leonard in part 1 of this 3 part series as they discuss risk assessment models for patients with FL. |
Evaluating the Options: Assessing Emerging Bispecific Antibody Treatments for Follicular Lymphoma
|
|
This second installment in a CME Outfitters’ series on follicular lymphoma examines emerging chemotherapy-sparing regimens incorporating bsAb constructs, both singly and in combination. Join Dr. Budde and Dr. Leonard in part 2 of this 3 part series as they discuss the safety and efficacy of bsAbs and how to integrate them into treatment plans for patients with FL. |
Targeting Treatment: Selecting Optimal Therapy for Vulnerable Patients
|
|
This final installment in a 3-part CME Outfitters’ series on follicular lymphoma will assess the needs of older patients with FL when creating treatment plans. Join Dr. Maddocks and Dr. Leonard as they discuss the impacts of aging on treatment selection and preferred treatments for older patients with FL. |
Real-world Tactics to Address Health Inequities in Prostate Cancer Care
|
|
In this CME Outfitters BriefCase, a faculty expert guides learners through a patient case scenario reflecting the impact of biases, disparities, and health inequities that reduce the quality of oncology care for racial and ethnic underserved patients with prostate cancer. This program provides actionable strategies, empowering attendees to recognize factors and implement changes in practice to improve prostate cancer treatment. |
Real-world Tactics to Address Health Inequities in Multiple Myeloma Care
|
|
In this CME Outfitters BriefCase, faculty experts guide learners through a patient case scenario reflecting the impact of biases, disparities, and health inequities that reduce the quality of oncology care for racial and ethnic underserved patients with multiple myeloma. This program provides actionable strategies, empowering attendees to recognize factors and implement changes in practice to improve multiple myeloma treatment. |
Real-world Tactics to Address Health Inequities in Melanoma Care
|
|
In this CME Outfitters BriefCase, a faculty expert guides learners through a patient case scenario reflective of the impact of biases, disparities, and health inequities that reduce the quality of oncology care for racial and ethnic underserved patients with melanoma. This program provides actionable strategies, empowering attendees to recognize factors and implement changes in practice to improve melanoma treatment. |
Real-world Tactics to Address Health Inequities in Lung Cancer Care
|
|
In this CME Outfitters BriefCase, a faculty expert guides learners through a patient case scenario reflecting the impact of biases, disparities, and health inequities that reduce the quality of oncology care for racial and ethnic underserved patients with lung cancer. This program provides actionable strategies, empowering attendees to recognize factors and implement changes in practice to improve lung cancer treatment. |
Degendering Symptom Assessment to Appropriately Evaluate for Malignancies
|
|
In this CMEO BriefCase, faculty use case-based learning to demonstrate the challenges specifically related to gender assumptions that transgender and non-binary patients encounter when trying to access health care. Faculty provide learners with best practices on approaching conversations about cancer screening based on anatomy present, not by gender. |
Addressing Disparities in Care: Assessing Patient Characteristics When Determining Next Steps for Anticoagulant Treatment Selection
|
|
The second installment of this CME Outfitters BriefCase series introduces Gordon, a 67-year-old Black man who complains of recent pain and swelling in his right leg, and explores this case with a focus on the impact of racial and ethnic disparities on the care of individuals who are candidates for anticoagulation therapy, and applying patient selection criteria for anticoagulation treatment that minimizes disparities and unconscious bias to optimize patient outcomes. |
Racial and Ethnic Disparities and Health Inequities in Prostate Cancer
|
|
In this CME Outfitters podcast, expert faculty review recent data and discuss the impact of biases, disparities, and health inequities that reduce the quality of oncology care for racial and ethnic underserved patients with prostate cancer. This program sets the stage for intervention, empowering attendees to recognize and consider factors to improve prostate cancer treatment. |
Racial and Ethnic Disparities and Health Inequity in Lung Cancer
|
|
In this CME Outfitters podcast, expert faculty review recent data and discuss the impact of biases, disparities, and health inequities that reduce the quality of oncology care for underserved racial and ethnic underserved patients with lung cancer. This program sets the stage for intervention, empowering attendees to recognize and consider factors to improve lung cancer treatment. |
Racial and Ethnic Disparities and Health Inequities in Multiple Myeloma
|
|
In this CME Outfitters podcast, expert faculty review recent data and discuss the sweeping impact of biases, disparities, and health inequities that reduce the quality of oncology care for racial and ethnic underserved patients with multiple myeloma. This program sets the stage for intervention, empowering attendees to recognize and consider factors to improve multiple myeloma treatment. |
What's Next for the Treatment of ccRCC? HIF-2α Inhibitors: Angiogenesis, Tumorigenesis, and Emerging Agents
|
|
This CMEOCast podcast focuses on the function of critical components of the VHL-HIF2α-VEGF axis and the potential value of HIF-2α inhibitors in the treatment ofVHL disease-associated tumors and ccRCC. |
Management of Patients with Metastatic Castration-Sensitive Prostrate Cancer
|
|
In this CME Outfitters podcast, expert faculty focus on patient selection criteria for second-generation antiandrogen therapy and the role of molecular testing risk stratification of patients with metastatic CSPC. |
Sorting Out the Androgen Deprivation Therapy Options for Locally Advanced CSPC
|
|
Despite the development of investigational and therapeutic options for prostate cancer, a lack of consensus among clinicians regarding patient management in early disease stages remains. Patients with locally advanced or metastatic castration-sensitive prostate cancer should receive androgen deprivation therapy (ADT) after definitive therapy, and it is imperative that clinicians consider luteinizing hormone releasing hormone (LHRH) antagonists in patients with major adverse cardiovascular events (MACE) risk factors. Additionally, must weigh factors that might negatively impact ADT adherence against the choice of ADT. This CMEOCast episode will aim to improve knowledge and competence in integrating the latest data on the management of patients with early-stage prostate cancer by evaluating strategies for its management and differentiating the potential for adverse effects between androgen deprivation therapies |
Treatment Options and Clinical Dilemmas in Biochemical Recurrence
|
|
This CME Outfitters podcast focuses on how clinicians can individualize treatment decisions based on the use of risk assessment algorithms and advanced imaging techniques with greater ability to detect the sites and extent of disease at BCR. These tools have already demonstrated the ability to change treatment decisions and will substantially impact the management of patients with BCR after radical prostatectomy. |
Disease States and Staging of Castration-Sensitive Prostate Cancer
|
|
The first episode of this CME Outfitters podcast series on castration-sensitive prostate cancer (CSPC) will outline the current state of staging in CSPC and clarify the findings of reports detailing the pathology of prostate cancer specimens. |
Animations
The Role of Antibody Drug Conjugates in Advanced Non-Small Cell Lung Cancer: 3D Animation
View this animation to understand the mechanisms and characteristics of antibody drug conjugates (ADCs) in NSCLC
Whiteboard Animation: Real-World Evidence in Metastatic Breast Cancer
In oncology, real-world evidence, or RWE, refers to evidence derived from the use and analysis of real-world data, or RWD, which are data obtained outside the context of randomized controlled trials, or RCTs. View this animation to learn more about RWE in Metastatic Breast Cancer.
Patient Resources
You may have a million questions about bladder cancer, but where do you to start? CME Outfitters talked with patients and caregivers to find out what information was useful for them and what questions they asked their physician and care team during visits. We compiled resources and questions to ask that we hope will be helpful as you and your family navigate this journey.
Resources
Ovarian Cancer
Breast Cancer
- American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP): Guideline on estrogen and progesterone receptor testing in breast cancer
- ASCO/CAP: Clinical practice guideline focused update on human epidermal growth factor receptor 2 testing in breast cancer, update
- ASCO: Clinical practice guideline update on recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases
- ASCO: Clinical practice guideline update on systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer
- ASCO: Guideline on management of male breast cancer
- ASCO: Endorsement of the Cancer Care Ontario guideline –Role of patient and disease factors in adjuvant systemic therapy decision making for early-stage, operable breast cancer, update (2019)
- Guidelines and Strategies for Cultural Competency
- Guidelines and Strategies for Cultural Competency: Additional Resources
- Ascertaining the Burden of Social Determinants of Health for Your Patients
Lung Cancer
- ASCO and Ontario Health (Cancer Care Ontario [CCO]): Joint guideline update on therapy for stage IV non-small-cell lung cancer without driver alterations
- National Cancer Institute (NCI): Non-small-cell lung cancer–Health professional version
- ASCO: Clinical practice guideline on systemic therapy for stage IV non-small-cell lung cancer, update
- American Thoracic Society (ATS): Official policy statement for evaluating molecular biomarkers for the early detection of lung cancer
- European Society for Medical Oncology (ESMO): Metastatic non-small-cell lung cancer –Clinical practice guidelines for diagnosis, treatment, and follow-up
Discover additional accredited CME/CE activities and patient resources on the Virtual Education Hub.